Skip to main content
NCBI home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 1998 Dec 7;11(1):10–16. doi: 10.1002/(SICI)1098-2825(1997)11:1<10::AID-JCLA3>3.0.CO;2-O

Molecular genetic analysis in the pathologic evaluation of solid tumors: Theory and practice

Daniel W Visscher 1,✉, Fazlul H Sarkar 1, John D Crissman 1
PMCID: PMC6760710  PMID: 9021519

The content is available as a PDF (38.5 KB).

References

  • 1. Stephenson CF, Bridge JA, Sandberg AA: Cytogenetic and pathologic aspects of Ewing's sarcoma and neuroectodermal tumors. Hum Pathol 23: 1270–1277, 1992. [DOI] [PubMed] [Google Scholar]
  • 2. Diffin F, Porter H, Mott MG, Berry PJ, Brown KW: Rapid and specific diagnosis of t(ll;22) translocation in paediatric Ewing's sarcoma and primitive neuroectodermal tumours using RNA‐PCR. J Clin Pathol 47: 562–564, 1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Gerald WL, Ladanyi M, de Alava E, Rosai J: Desmoplastic small roundcell tumor: A recently recognized tumor type associated with a unique gene fusion. Adv Anat Pathol 2: 341–345, 1995. [Google Scholar]
  • 4. Scrable H, Witte D, Shimada Seemayer T, Sheng WW, Soukup S, Koufos A, Houghton P, Lampkin B, Lavenee W: Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes Cancer 1: 23, 1989. [DOI] [PubMed] [Google Scholar]
  • 5. Pieretti M, Powell DE, Gallion HH, Case EA, Conway PS, Turker MS: Genetic alterations on chromosome 17 distinguish different types of epithelial ovarian tumors. Hum Pathol 26: 393–397, 1995. [DOI] [PubMed] [Google Scholar]
  • 6. Sandberg AA: Chromosomes and hereditary predisposition to cancer. Heme Oncol Ann 2: 141, 1994. [Google Scholar]
  • 7. O'Connell P, Pekkel V, Fuqua SAW, Osborne CK, Allred DC: LOH on chromosome 14q is associated with invasive but not metastatic breast cancer. Mod Pathol 9: 22A, 1996. (abst). [Google Scholar]
  • 8. Wood DP, Banks ER, Humphreys S, Rangnekar VM: Sensitivity of immunohistochemistry and polymerase chain reaction in detecting prostate cancer cells in bone marrow. J Histochem Cytochem 42: 505–511, 1994. [DOI] [PubMed] [Google Scholar]
  • 9. Mansi JL, Easton D, Berger U, Gazet JC, Ford HT, Dearnaley D, Coombes RC: Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years' follow up. Eur J Cancer 27: 1552–1555, 1991. [DOI] [PubMed] [Google Scholar]
  • 10. Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, O'Toole KM, McMahon D, Benson MC, Buttyan R: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase‐PCR assay. Urology 43: 765–775, 1994. [DOI] [PubMed] [Google Scholar]
  • 11. Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, Goodman SN, Sidransky D: Molecular assessment of histopathological staging in squamous‐cell carcinoma of the head and neck. N Engl J Med 332: 429–435, 1995. [DOI] [PubMed] [Google Scholar]
  • 12. Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelstein B: Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256: 102–105, 1992. [DOI] [PubMed] [Google Scholar]
  • 13. Vogelstein B, Kinzler KW: P 53 function and dysfunction. Cell 70: 523–526, 1992. [DOI] [PubMed] [Google Scholar]
  • 14. Eyfjörd JE, Thorlacius S, Steinarsdottir M, Valgardsdottir R, Ögmundsdottir HM, Anamthawat‐Jonsson K: P53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 55: 646–651, 1995. [PubMed] [Google Scholar]
  • 15. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Mercus JN, Schwartz L, Chen LC, Mayal BH: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84: 845–855, 1992. [DOI] [PubMed] [Google Scholar]
  • 16. Battifora H: P53 immunohistochemistry: A word of caution. Hum Pathol 25: 435–437, 1994. [DOI] [PubMed] [Google Scholar]
  • 17. Wynford‐Thomas D: P53 in tumour pathology: Can we trust immunocytochemistry. J Pathol 166: 329–330, 1992. [DOI] [PubMed] [Google Scholar]
  • 18. Hall PA, Lane DP: P53 in tumour pathology: Can we trust immunohistochemistry?—Revisited. J Pathol 172: 1–4, 1994. [DOI] [PubMed] [Google Scholar]
  • 19. Xu L, Chen Y‐T, Huvos AG, Zlotolow IM, Rettig WJ, Old LJ, Garin‐Chesa P: Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations. Diagn Mol Pathol 3: 83–92, 1994. [DOI] [PubMed] [Google Scholar]
  • 20. Jacquemier J, Molès Penault‐Llorca F, Adèlaide J, Torrente M, Viens P, Birnbaum D, Theillet C: P53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: Comparison of staining and PCR‐SSCP results. Br J Cancer 69: 846–852, 1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Baas IO, Mulder J‐WR, Offerhaus GJA, Vogelstein B, Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172: 5–12, 1994. [DOI] [PubMed] [Google Scholar]
  • 22. Lambkin HA, Mothersill CM, Kelehan P: Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection. J Pathol 172: 13–18, 1994. [DOI] [PubMed] [Google Scholar]
  • 23. Lane DP: On the expression of the p53 protein in human cancer. Mol Biol Rep 19: 23–29, 1994. [DOI] [PubMed] [Google Scholar]
  • 24. Sommer SS, Cunningham J, McGovern RM, Saitoh S, Schroseder JJ, Wold LE, Kovach JS: Pattern of p53 gene mutations in breast cancers of women in the midwestern United States. J Natl Cancer Inst 84: 246–252, 1992. [DOI] [PubMed] [Google Scholar]
  • 25. Tsuda H, Hirohashi S: Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. Int J Cancer 57: 498–503, 1994. [DOI] [PubMed] [Google Scholar]
  • 26. Shiao Y‐H, Chen VW, Scheer WD, Wu XC, Correa P: Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res 55: 1485–1490, 1995. [PubMed] [Google Scholar]
  • 27. Merlo GR, Bernardi A, Diella F, Venesio T, Cappa APM, Callahan R, Liscia DS: In primary human breast carcinomas mutations in exons 5 and 6 of the p53 gene are associated with a high S‐phase index. Int J Cancer 54: 531–535, 1993. [DOI] [PubMed] [Google Scholar]
  • 28. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC Nakamura Y, White R: Allelotype of colorectal carcinomas. Science 24: 207–211, 1989. [DOI] [PubMed] [Google Scholar]
  • 29. Grignon DJ, Hammond EH: College of American pathologists conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the prostate cancer working group. Arch Pathol Lab Med 119: 1122–1126, 1995. [PubMed] [Google Scholar]
  • 30. Vogelstein B, Kinzler KW: Has the breast cancer gene been found. Cell 79: 1–3, 1994. [DOI] [PubMed] [Google Scholar]
  • 31. Wiggs J, Nordenskj_ld M, Yandell D, Rapaport J, Grondin V, et al: Prediction of the risk of hereditary retinoblastoma, using DNA polymorphisms within the retinoblastoma gene. N Engl J Med 318: 151–157, 1988. [DOI] [PubMed] [Google Scholar]
  • 32. Saito H, Inazawa J, Saito S, Kasumi F, Koi S, Sagae S, Kudo R, Saito J, Noda K, Nakamura Y: Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2‐cM region on 17q21.3 often and commonly deleted in tumors. Cancer Res 53: 3382–3385, 1993. [PubMed] [Google Scholar]
  • 33. Borg A, Zhang Q‐X, Johannsson O, Olsson H: High frequency of allelic imbalance at the BRCA1 region on chromosome 17q in both familial and sporadic ductal breast carcinomas. J Natl Cancer Inst 86: 792–794, 1994. [DOI] [PubMed] [Google Scholar]
  • 34. Miki Y, Swensen J, Shattuck‐Eidens D, Futreal A, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen‐Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA‐1. Science 266: 66–69, 1994. [DOI] [PubMed] [Google Scholar]
  • 35. Nowak R: Many mutations may make test difficult. Science 266: 1470, 1994. [DOI] [PubMed] [Google Scholar]
  • 36. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC: The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature Genet 11: 1–3, 1995. [DOI] [PubMed] [Google Scholar]
  • 37. Gao X, Zacharek A, Salkowski A, Grignon DJ, Sakr W, Porter AT, Honn KV: Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 55: 1002–1005, 1995. [PubMed] [Google Scholar]
  • 38. Biesecker BB, Boehnke M, Calzone K, Markel DS, Garber JE, Collins FS, Weber BL: Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA 269: 1970–1974, 1993. [PubMed] [Google Scholar]
  • 39. Fishel R, Lescoe MK, Rao MRS, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75: 1027–1038, 1993. [DOI] [PubMed] [Google Scholar]
  • 40. Swift M, Morrell D, Massey RB, Chase CL: Incidence of cancer in 161 families affected by ataxia‐telangiectasia. JAMA 325(26): 1831–1836, 1991. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES